Launches of at Least 15 New Biologic Therapies By 2017 Will Expand Treatment Options for Immune and Inflammatory Diseases
Posted on: Monday, 12 May 2008, 09:00 CDT
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to the increasing uptake of currently-marketed biologic drugs, at least 15 new biologic therapies for immune and inflammatory diseases are expected to launch by 2017, compared to fewer than five oral agents.
The new Pharmacor report entitled Emerging Immunomodulators finds that sales of emerging immunomodulators for nine inflammatory diseases -- asthma, rheumatoid arthritis, chronic obstructive pulmonary disease, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and systemic lupus erythematosus -- will exceed $6 billion in 2017. Although the use of emerging biologic agents will remain restricted to moderate-to-severe cases in most indications, they will expand treatment options for patients failing existing therapies and their high prices, as well as the need for continuous administration, will drive robust market growth.
The report also finds that the dominance of TNF-alpha inhibitors over other immunomodulators will persist in the next decade, as sales for TNF-alpha inhibitors will exceed $17 billion in major-market class sales in 2017. Despite the availability of three marketed agents, the report forecasts that a novel TNF-alpha inhibitor, Centocor/Schering-Plough/Mitsubishi Tanabe/ Janssen's golimumab, is positioned to become a blockbuster.
"The greatest commercial potential exists for TNF-alpha and interleukin inhibitors due to their applicability across several immune indications and their promising risk/benefit profiles," said Irene Koulinska, M.D., analyst at Decision Resources. "New biologic immunomodulatory agents will enter the market as late-line treatment options for indications with marketed TNF-alpha inhibitors such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis and ankylosing spondylitis."
Based on this report, Decision Resources is offering an in-depth webinar entitled Emerging Targeted Therapies in Immune Indications: How Will Immune Disease Markets Respond to the Entry of at Least 15 New Immunomodulators by 2017? The webinar, presented by Dr. Koulinska, will be held at 10 AM (EST) on May 15, 2008. To register, visit http://www.decisionresources.com/.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
- As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
- Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
- Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
- Peripheral Arterial Disease Report is Critical for Evaluating the Impact of Clinical Attributes on Physician Prescribing of Emerging Agents
- New Setback For UCB's Cimzia Shifts Competitive Landscape For TNF-Alpha Inhibitor Drug Class
- Greater Uptake of Abbott/Eisai's Humira in the Treatment of Rheumatoid Arthritis and Crohn's Disease Will Drive Growth in the TNF-Alpha Inhibitor Market Through 2011
- Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF-Alpha Inhibitors to $1.3 Billion in the Market to Treat Crohn's Disease
- Concentrating on Extending the Shelf Life of Drugs Such As Antidepressants (the SSRIs and SNRIs), Anti-Tnf-Alpha Agents for Inflammatory Diseases, and Angiotensin II Antagonists Used in Cardiovascular Indications
- Decision Resources and PharMetrics Announce the Availability of First DecisionMETRICS Indication -- Dyslipidemia
 |
 |
User Comments (0)
RSS Feeds